Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples